Comparative Pharmacology
Head-to-head clinical analysis: PEMETREXED versus PEMETREXED DISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEMETREXED versus PEMETREXED DISODIUM.
PEMETREXED vs PEMETREXED DISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. It inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), leading to inhibition of de novo purine and pyrimidine synthesis.
Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. It inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), thereby inhibiting de novo synthesis of thymidine and purine nucleotides.
500 mg/m2 IV over 10 minutes on Day 1 of each 21-day cycle, with folic acid and vitamin B12 supplementation.
500 mg/m2 intravenously over 10 minutes on Day 1 of each 21-day cycle, with vitamin B12 and folic acid supplementation.
None Documented
None Documented
Clinical Note
moderatePemetrexed + Digoxin
"Pemetrexed may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePemetrexed + Digitoxin
"Pemetrexed may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePemetrexed + Deslanoside
"Pemetrexed may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePemetrexed + Acetyldigitoxin
"Pemetrexed may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life is approximately 3.5 hours in patients with normal renal function (creatinine clearance ≥60 mL/min). Clinically, half-life is prolonged in renal impairment (up to 20 hours in severe impairment), requiring dose adjustment.
Terminal half-life is 3.5 hours in patients with normal renal function. Increases in renal impairment (up to 20 hours if CrCl <45 mL/min).
Primarily eliminated unchanged in urine (70-90% of dose via renal excretion over 24 hours); minimal biliary/fecal excretion (<5%).
Primarily renal excretion (70-90% as unchanged drug within 24 hours). Biliary/fecal excretion accounts for <5%.
Category C
Category C
Antineoplastic Antifolate
Antineoplastic Antifolate